A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

BACKGROUND: This first-in-human study evaluated AMG 208, a small-molecule MET inhibitor, in patients with advanced solid tumors. METHODS: Three to nine patients were enrolled into one of seven AMG 208 dose cohorts (25, 50, 100, 150, 200, 300, and 400 mg). Patients received AMG 208 orally on days 1 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, David S., Rosen, Peter, Lockhart, A. Craig, Fu, Siqing, Janku, Filip, Kurzrock, Razelle, Khan, Rabia, Amore, Benny, Caudillo, Isaac, Deng, Hongjie, Hwang, Yuying C., Loberg, Robert, Ngarmchamnanrith, Gataree, Beaupre, Darrin M., Lee, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621921/
https://www.ncbi.nlm.nih.gov/pubmed/26155941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621921/
https://www.ncbi.nlm.nih.gov/pubmed/26155941

Ejemplares similares